NYSE · HCA
Healthcare · Medical - Care Facilities
$427.71
Down-$1.33 (-0.31%)
Updated Sep 19, 2026, 9:23 PM
SID Score
6.4/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
HCA closed at $427.71 after 20 trading sessions, down 0.34% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $429.17 | $436.14 | $425.37 | $427.71 | 5.45M |
| Sep 17, 2026 | $431.99 | $433.51 | $426.52 | $429.04 | 1.19M |
| Sep 16, 2026 | $420.69 | $433.70 | $420.00 | $430.43 | 1.37M |
| Sep 15, 2026 | $419.00 | $426.22 | $409.735 | $423.82 | 1.26M |
| Sep 14, 2026 | $429.96 | $433.80 | $420.00 | $425.49 | 1.31M |
| Sep 11, 2026 | $423.79 | $429.42 | $420.79 | $426.94 | 1.32M |
| Sep 10, 2026 | $422.61 | $426.81 | $415.04 | $421.21 | 1.41M |
| Sep 9, 2026 | $398.47 | $426.83 | $396.00 | $421.83 | 2.15M |
| Sep 8, 2026 | $401.55 | $411.75 | $397.60 | $402.02 | 1.76M |
| Sep 4, 2026 | $404.30 | $419.57 | $401.00 | $405.00 | 971.43K |
| Sep 3, 2026 | $406.80 | $413.13 | $401.41 | $409.20 | 1.36M |
| Sep 2, 2026 | $412.46 | $414.495 | $396.77 | $402.06 | 1.54M |
| Sep 1, 2026 | $418.43 | $423.4199 | $412.29 | $413.58 | 1.26M |
| Aug 31, 2026 | $415.40 | $419.81 | $414.12 | $414.45 | 1.31M |
| Aug 28, 2026 | $423.76 | $426.37 | $416.52 | $417.82 | 1M |
| Aug 27, 2026 | $424.61 | $426.57 | $417.92 | $419.34 | 975.11K |
| Aug 26, 2026 | $427.50 | $433.50 | $424.50 | $427.16 | 1.32M |
| Aug 25, 2026 | $426.97 | $430.60 | $425.89 | $428.76 | 790.22K |
| Aug 24, 2026 | $433.25 | $436.50 | $427.23 | $429.24 | 1.32M |
| Aug 21, 2026 | $409.56 | $431.40 | $408.94 | $429.19 | 2.06M |
The latest Smart Investors Daily articles mentioning HCA.
HCA research
Company profile and research snapshot.
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of December 2024, the firm owned and operated 190 hospitals, 124 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 18, 2026 | Leerink Partners | Outperform | — |
| Sep 8, 2026 | RBC Capital | Outperform | — |
| Aug 20, 2026 | JP Morgan | Neutral | — |
| Aug 3, 2026 | Wells Fargo | Equal-Weight | — |
| Jul 28, 2026 | Goldman Sachs | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 18, 2026
HCA Healthcare (NYSE:HCA) CFO Mike Marks said the hospital operator is navigating a changing policy environment in 2026 while continuing to see solid underlying demand for services outside of the health insurance exchanges. Speaking at an investor conference, Marks described the expiration of enhan
Yahoo · Sep 16, 2026
Alluvium Asset Management, an asset management company, released its “Conventum – Alluvium Global Fund” second-quarter 2026 investor letter. The letter can be downloaded here. The second quarter reflected a sharp shift from geopolitical uncertainty and oil market volatility to a powerful equity rally led by semiconductor companies. Despite the broader market strength, the Fund declined […]
SeekingAlpha · Sep 16, 2026
HCA Healthcare, Inc. (HCA) 2026 Jefferies Healthcare Services and Technology Conference September 15, 2026 2:50 PM EDTCompany ParticipantsMike Marks - CFO...
Yahoo · Sep 16, 2026
Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF) President and CTO Nicolas Loebel spoke with Proactive's Stephen Gunnion about the company's photodisinfection technology, top-line results from its pivotal phase III LANTERN trial, and the commercial opportunity for Steriwave. The 5,188-patient phase III LANTERN study, conducted across 18 major US and Canadian hospitals, showed a 40.5% lower risk of 30-day surgical site infections. Loebel said the findings "change the entire nature of the company," highlighting a favourable safety profile with no device-related serious adverse events. He discussed the significance of 14 HCA Healthcare hospitals participating in the trial and the potential pathway to the US market. Steriwave remains investigational in the US and subject to FDA approval, with Ondine planning to take the full data package forward to the FDA, having already secured Fast Track and Qualified Infectious Disease Product designations. Loebel also outlined Ondine's commercial activities outside the US and the broader potential for photodisinfection in areas including intensive care, describing a recurring-revenue model combining reusable light devices with patient-specific consumables, with growth potentially coming from both new hospital adoption and increased treatments within each hospital. For more interviews and company updates, visit Proactive’s YouTube channel. Give the video a like, subscribe to the channel and enable notifications so you don’t miss future content. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy #OndineBiomedical #StereoWave #LANTERNTrial #Phase3Trial #SurgicalSiteInfections #InfectionPrevention #PhotoDisinfection #AntimicrobialResistance #HealthcareTechnology #MedTech #FDA #ClinicalTrials #HospitalInfections #HealthcareInnovation #Biotech #Investing #InvestorNews #ProactiveInvestors
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HCA.
